0001104659-23-082727.txt : 20230720 0001104659-23-082727.hdr.sgml : 20230720 20230720161728 ACCESSION NUMBER: 0001104659-23-082727 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230718 FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martins Eduardo Bruno CENTRAL INDEX KEY: 0001670431 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41742 FILM NUMBER: 231099915 MAIL ADDRESS: STREET 1: 350 CAMBRIDGE AVE, SUITE 350 CITY: PALO ALTO STATE: CA ZIP: 94306 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sagimet Biosciences Inc. CENTRAL INDEX KEY: 0001400118 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205991472 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 155 BOVET RD., SUITE 303 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: (650) 561-8600 MAIL ADDRESS: STREET 1: 155 BOVET RD., SUITE 303 CITY: SAN MATEO STATE: CA ZIP: 94402 FORMER COMPANY: FORMER CONFORMED NAME: 3-V Biosciences, Inc. DATE OF NAME CHANGE: 20070521 4 1 tm2321276-17_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-07-18 0 0001400118 Sagimet Biosciences Inc. SGMT 0001670431 Martins Eduardo Bruno SAGIMET BIOSCIENCES INC. 155 BOVET RD., SUITE 303 SAN MATEO CA 94402 0 1 0 0 Chief Medical Officer 0 Stock Option (Right to Buy) 6.36 2023-07-18 4 D 0 198132 0 D 2031-02-18 Common Stock 198132 0 D Stock Option (Right to Buy) 6.36 2023-07-18 4 A 0 198132 0 A 2031-02-18 Series A Common Stock 198132 198132 D Stock Option (Right to Buy) 13.51 2023-07-18 4 D 0 44009 0 D 2033-04-19 Common Stock 44009 0 D Stock Option (Right to Buy) 13.51 2023-07-18 4 A 0 44009 0 A 2033-04-19 Series A Common Stock 44009 44009 D Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. 25% of the shares underlying this option vested and became exercisable on February 16, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 20, 2023, subject to the Reporting Person's continued service on each such vesting date. /s/ Dennis Hom, Attorney-in-Fact 2023-07-20